Dentsply International Inc. (NASDAQ:XRAY) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 8,288,029 shares, an increase of 28.1% from the September 15th total of 6,471,038 shares. Approximately 3.6% of the shares of the stock are sold short. Based on an average trading volume of 1,480,437 shares, the days-to-cover ratio is presently 5.6 days.

In other news, VP Rainer Berthan sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $61.12, for a total transaction of $305,600.00. Following the completion of the sale, the vice president now directly owns 34,370 shares in the company, valued at approximately $2,100,694.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Maureen J. Macinnis sold 45,100 shares of the company’s stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $60.55, for a total value of $2,730,805.00. Following the sale, the senior vice president now owns 36,730 shares of the company’s stock, valued at $2,224,001.50. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Creative Planning increased its position in shares of Dentsply International by 41.7% in the third quarter. Creative Planning now owns 5,774 shares of the company’s stock worth $343,000 after buying an additional 1,699 shares during the period. Reilly Herbert Faulkner III boosted its stake in Dentsply International by 2.6% in the third quarter. Reilly Herbert Faulkner III now owns 67,691 shares of the company’s stock worth $4,023,000 after buying an additional 1,744 shares in the last quarter. Contravisory Investment Management Inc. boosted its stake in Dentsply International by 8.9% in the third quarter. Contravisory Investment Management Inc. now owns 3,108 shares of the company’s stock worth $185,000 after buying an additional 254 shares in the last quarter. First Mercantile Trust Co. boosted its stake in Dentsply International by 18.6% in the third quarter. First Mercantile Trust Co. now owns 65,994 shares of the company’s stock worth $3,922,000 after buying an additional 10,347 shares in the last quarter. Finally, Telemus Capital LLC boosted its stake in Dentsply International by 0.4% in the third quarter. Telemus Capital LLC now owns 7,852 shares of the company’s stock worth $467,000 after buying an additional 35 shares in the last quarter. Institutional investors and hedge funds own 94.58% of the company’s stock.

Shares of Dentsply International (NASDAQ:XRAY) opened at 57.82 on Friday. Dentsply International has a 1-year low of $53.43 and a 1-year high of $65.83. The stock has a 50 day moving average price of $59.86 and a 200 day moving average price of $61.32.

Dentsply International (NASDAQ:XRAY) last posted its quarterly earnings data on Friday, August 5th. The company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.06. Dentsply International had a net margin of 11.99% and a return on equity of 9.18%. The business earned $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the firm posted $0.73 earnings per share. The business’s revenue for the quarter was up 46.4% compared to the same quarter last year. Equities analysts forecast that Dentsply International will post $2.76 EPS for the current year.

The company also recently disclosed a dividend, which will be paid on Friday, October 14th. Shareholders of record on Friday, September 30th will be given a $0.0775 dividend. The ex-dividend date of this dividend is Wednesday, September 28th. Dentsply International’s dividend payout ratio (DPR) is currently 14.49%.

XRAY has been the subject of several recent analyst reports. Bank of America Corp. initiated coverage on Dentsply International in a research report on Monday, September 12th. They set a “buy” rating and a $70.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Dentsply International in a research report on Thursday, September 22nd. They set a “neutral” rating and a $65.00 price objective for the company. Zacks Investment Research downgraded Dentsply International from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. Piper Jaffray Cos. restated a “buy” rating on shares of Dentsply International in a research report on Monday, June 27th. Finally, Barrington Research downgraded Dentsply International from an “outperform” rating to a “market perform” rating in a research report on Monday, August 8th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $66.91.

About Dentsply International

DENTSPLY SIRONA Inc, formerly DENTSPLY International Inc, designs, develops, manufactures and markets a range of consumable dental products for the professional dental market. The Company also manufactures and markets consumable medical device products consisting mainly of urological catheters and certain surgical products.

5 Day Chart for NASDAQ:XRAY

Receive News & Stock Ratings for Dentsply International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply International Inc. and related stocks with our FREE daily email newsletter.